Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.
December 31 2018 - 7:00AM
Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals,
Inc.) (NASDAQ: IMMY) announced it has formally changed its name and
that it will trade as “HROW” on The NASDAQ Capital Markets
beginning at market open January 2, 2019.
Mark L. Baum, CEO of Harrow Health, stated, “Our
new name reflects our business model of creating, investing in,
operating and growing a diversified portfolio of healthcare
businesses that meet the needs of healthcare providers and patients
across America. The future of healthcare involves rethinking our
current paradigm, creating patient-centric solutions, and
motivating the best partners to act to turn vision into reality.
I’ve never been more enthusiastic about our ability to execute our
strategy and the value Harrow Health will deliver over many years
to come.”
Harrow Health’s businesses and subsidiaries each
have strong brand equity and will continue to operate under the
Harrow Health corporate umbrella using their existing names. This
includes Harrow Health’s wholly-owned subsidiaries ImprimisRx, the
nation’s leading ophthalmology pharmaceutical compounding business,
and Park Compounding. Harrow Health’s equity interests and
royalty-rights in Eton Pharmaceuticals, Surface Pharmaceuticals,
Melt Pharmaceuticals, Mayfield Pharmaceuticals, and Radley
Pharmaceuticals remain in Harrow Health as well.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) owns a
portfolio of healthcare businesses, including the nation’s leading
ophthalmology pharmaceutical compounding business, ImprimisRx. The
company holds large equity positions in Eton Pharmaceuticals,
Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield
Pharmaceuticals and Radley Pharmaceuticals, companies founded as
subsidiaries of Harrow Health. The Company also owns royalty rights
in certain 505(b)(2) drug candidates being developed by Eton,
Surface, Melt, Mayfield and Radley. Harrow intends to create,
invest in and grow paradigm shifting health care businesses that
put patients first. For more information about Harrow Health,
please visit the Investor Relations section of the corporate
website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Such documents may be read free of
charge on the SEC's web site at www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Investor ContactJon Patton
jpatton@harrowinc.com858.704.4587
Source: Harrow Health, Inc.
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2024 to Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jun 2023 to Jun 2024